Booting Earth Optimization System
Thank you for your patience. Your civilization is very important to us.
Ivosidenib (IDH1 Inhibitor)
Treatment for Gallbladder and biliary tract cancer
Typical Dosage: 500 mg orally once daily
Effectiveness
40%
Safety Score
45%
Clinical Trials
20
Participants
300
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
45
DangerousModerateSafe
Treatment Details
Dosage Range
500 mg orally once daily
Time to Effect
2-4 months
Treatment Duration
Until progression or unacceptable toxicity (6-18+ months)
Evidence Quality
MODERATEConfidence Score
75%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$270,000
Monitoring:$15,000
Side Effect Mgmt:$5,000
Total Annual:$290,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
POORICER
$900,000/QALY
QALYs Gained
0.2
Outcome-Based Costs
Cost per Responder
$14,500,000
Cost per Remission
$58,000,000
Comparison vs Placebo + Best Supportive Care
Cost Difference
+$280,000/year
More expensive
QALY Difference
+0.20 QALYs
Better outcomes
Dominance
No dominance
Ivosidenib (IDH1 Inhibitor) Outcomes
for Gallbladder and biliary tract cancer
Efficacy Outcomes
Overall Effectiveness
+40%
Response Rate
+2%
Remission Rate
+0.5%
Common Side Effects
Nausea
+35%
Fatigue
+35%
Diarrhea
+30%
Abdominal pain
+25%
QTc prolongation
+12%
Sources:
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov